Want to see RFL full AI Analyst Report?
RFL Stock Chart & Stats
$2.13
$0.08(3.76%)
At close: 4:00 PM EDT
$2.13
$0.08(3.76%)
Day’s Range― - ―
52-Week Range$1.12 - $3.96
Previous CloseN/A
Volume22.68K
Average Volume (3M)81.34K
Market Cap
$109.22M
Enterprise Value$40.59
Total Cash (Recent Filing)$30.50M
Total Debt (Recent Filing)$610.00K
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Nov 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding51,212,833
10 Day Avg. Volume101,467
30 Day Avg. Volume81,339
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.53
Price to Sales (P/S)54.22
P/FCF Ratio-2.63
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical/pipeline MilestoneCompletion of the pivotal Phase 3 study plus a pre-NDA meeting and FDA acknowledgement of expanded access is a structural shift toward commercialization. This advances regulatory pathway clarity and creates durable optionality for future revenues, licensing, or partnering over months.
Balance Sheet StrengthVery low leverage provides financial flexibility to fund remaining development, commercialization steps, or real estate operations without immediate refinancing. A strong cash/reserve position relative to debt materially reduces insolvency risk over the medium term.
Diversified Business ModelA dual exposure to biotech upside (milestones, licensing, royalties) and real estate income/rental revenue smooths cash flow volatility and creates multiple value realization pathways, sustaining company viability while biotech assets mature.
Bears Say
Cash Burn / Weak Cash GenerationSustained negative operating and free cash flow means the company relies on its balance sheet or external financing to fund activities. Over several months this can force asset sales, dilution, or borrowing if pipeline commercialization and real estate income don't cover outflows.
Poor Profitability & Revenue TrendsVery small and declining revenues versus large recurring losses indicate the core operations are not self-sustaining. Without durable revenue growth from commercialization or real estate, losses will likely continue and impede reinvestment or margin recovery.
Value Erosion / Negative ReturnsSharply negative ROE and declining equity/assets point to structural inability to generate shareholder returns from invested capital. This persistent value erosion can limit strategic options, raise dilution risk, and weaken investor confidence over the medium term.
Rafael Holdings News
RFL FAQ
What was Rafael Holdings Inc’s price range in the past 12 months?
Rafael Holdings Inc lowest stock price was $1.12 and its highest was $3.96 in the past 12 months.
What is Rafael Holdings Inc’s market cap?
Rafael Holdings Inc’s market cap is $109.22M.
When is Rafael Holdings Inc’s upcoming earnings report date?
Rafael Holdings Inc’s upcoming earnings report date is Nov 02, 2026 which is in 95 days.
How were Rafael Holdings Inc’s earnings last quarter?
Rafael Holdings Inc released its earnings results on Jun 11, 2026. The company reported -$0.082 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.082.
Is Rafael Holdings Inc overvalued?
According to Wall Street analysts Rafael Holdings Inc’s price is currently Overvalued.
Does Rafael Holdings Inc pay dividends?
Rafael Holdings Inc pays a Semiannually dividend of $0.02 which represents an annual dividend yield of N/A. See more information on Rafael Holdings Inc dividends here
What is Rafael Holdings Inc’s EPS estimate?
Rafael Holdings Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rafael Holdings Inc have?
Rafael Holdings Inc has 51,212,833 shares outstanding.
What happened to Rafael Holdings Inc’s price movement after its last earnings report?
Rafael Holdings Inc reported an EPS of -$0.082 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 19.101%.
Which hedge fund is a major shareholder of Rafael Holdings Inc?
Currently, no hedge funds are holding shares in RFL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rafael Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-14.90%
Trailing 12-Months
Company Description
Rafael Holdings Inc
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Technical Analysis
JW Mays
―
New England Realty Associates Partnershi
―
Fathom Holdings
―
Offerpad Solutions
―
Star Holdings
―
Ownership Overview
30.68% Insiders
3.46% Mutual Funds
<0.01% Other Institutional Investors
62.73% Public Companies and
Individual Investors